Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Hypertension defined as a mean in-clinic seated cuff Systolic Blood Pressure \>150 mmHg at Visit 3 (Randomisation visit)~2. Diagnosis of Type 2 diabetes mellitus~3. =18 years of age at the date of signing the informed consent~4. Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)~5. Ability to provide written informed consent~Exclusion criteria:~1. Pre-menopausal women (last menstruation \<=1 year prior to start of run-in period) who:~   1. are not surgically sterile; and/or~  2. are nursing or pregnant, or~  3. are of child-bearing potential and are NOT practicing acceptable means of birth control or do NOT plan to continue practising an acceptable method throughout the study.~   The only acceptable methods of birth control are:~  * Intrauterine device (IUD);~  * Oral contraceptives (started at least three months prior to start of run-in period)~  * Implantable or injectable contraceptives and~  * Estrogen patch~2. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 a.m.~3. Known or suspected secondary hypertension (e.g., renal artery stenosis, phaeochromocytoma)~4. Mean seated Systolic Blood Pressure (SBP) =180 mm Hg and/or mean seated Diastolic Blood Pressure (DBP) =110 mm Hg during any visit of the screening and placebo run-in periods~5. Patients with Type 1 diabetes mellitus~6. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine \>3.0 mg/dL (or \>265 µmol /L) or known creatinine clearance \<30 mL/min or clinical markers of severe renal impairment~7. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney~8. Clinically relevant hypokalaemia or hyperkalaemia~9. Uncorrected sodium or volume depletion~10. Primary aldosteronism~11. Hereditary fructose intolerance~12. Biliary obstructive disorders (e.g., cholestatis) or hepatic insufficiency~13. Congestive heart failure New York Heart Academy (NYHA) functional class CHF III-IV (Refer to Appendix 10.3)~14. Contraindication to a placebo run-in period (e.g., stroke with-in the past six months, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period)~15. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator~16. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve~17. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C \>10%~18. Patients who have previously experienced symptoms characteristic of angioedema during treatment with Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin-II receptor antagonists~19. History of drug or alcohol dependency within six months prior to signing the informed consent form~20. Concomitant administration of any medications known to affect blood pressure, except medications allowed by the protocol~21. Any investigational drug therapy within one month of signing the informed consent~22. Known hypersensitivity to any component of the study drugs (telmisartan, amlodipine, or placebo)~23. History of non-compliance or inability to comply with prescribed medications or protocol procedures~24. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan 80 / Amlodipine 10 (Type: EXPERIMENTAL): Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
- Amlodipine 10 (Type: ACTIVE_COMPARATOR): Amlodipine 5 for two weeks, then forced titration to Amlodipine 10

Based on this trial design, predict the completion outcome and termination type (if applicable).